Literature DB >> 2411995

[Blood-brain barrier and the penetration of cytostatic drugs].

C Unger, H Eibl, H W von Heyden, B Krisch, G A Nagel.   

Abstract

The penetration of 12 commonly used anticancer agents through the blood-brain barrier (BBB) was measured in a rat model using a single-injection tissue-sampling technique. Two of the tested drugs penetrated the barrier, but only to a limited extent. Entry of the drugs into the brain tissue critically depends on molecular weight and lipophilia of the respective test compound. For drugs with a molecular weight of less than 500, BBB simply behaves like an oil/water interphase, whereas drugs with a molecular weight greater than 500 are practically excluded from transport through the BBB even if they show a favourable oil/water partition coefficient. However, permeability of cytostatics was strongly increased if short chain alkylglycerols, up to final concentrations of about 0.3 mol/l were added to the injected solution. Under these conditions the Brain-Uptake-Index (BUI) reached values up to about 50% (cyclophosphamide), depending on lipid solubility and molecular dimension of the respective test compound and the alkyl chain length of the glycerol derivative.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2411995     DOI: 10.1007/bf01733202

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  21 in total

Review 1.  Properties and structural basis of simple diffusion pathways in the erythrocyte membrane.

Authors:  B Deuticke
Journal:  Rev Physiol Biochem Pharmacol       Date:  1977       Impact factor: 5.545

2.  Drug entry into the brain.

Authors:  S I Rapoport; K Ohno; K D Pettigrew
Journal:  Brain Res       Date:  1979-08-24       Impact factor: 3.252

3.  The interaction of small molecules with spin-labelled erythrocyte membranes.

Authors:  W L Hubbell; J C Metcalfe; S M Metcalfe; H M McConnell
Journal:  Biochim Biophys Acta       Date:  1970-12-01

4.  Lipid solubility and drug penetration of the blood brain barrier.

Authors:  W H Oldendorf
Journal:  Proc Soc Exp Biol Med       Date:  1974-12

5.  Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard.

Authors:  W H Oldendorf
Journal:  Brain Res       Date:  1970-12-01       Impact factor: 3.252

6.  [14C-labelled lecithin and lysolecithin].

Authors:  H Eibl; O Westphal
Journal:  Justus Liebigs Ann Chem       Date:  1967

Review 7.  The metabolic fate of cyclophosphamide.

Authors:  A R Torkelson; J A LaBudde; J H Weikel
Journal:  Drug Metab Rev       Date:  1974       Impact factor: 4.518

8.  Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening.

Authors:  E A Neuwelt; E Balaban; J Diehl; S Hill; E Frenkel
Journal:  Neurosurgery       Date:  1983-06       Impact factor: 4.654

9.  Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier.

Authors:  E A Neuwelt; P A Barnett; D D Bigner; E P Frenkel
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

Review 10.  Synthesis of glycerophospholipids.

Authors:  H Eibl
Journal:  Chem Phys Lipids       Date:  1980-06       Impact factor: 3.329

View more
  8 in total

1.  [Changes in the blood-cerebrospinal fluid barrier for serum proteins in children with acute lymphatic leukemia].

Authors:  R Ludwig; R Kretzmann; R Burger; W E Brandeis
Journal:  Klin Wochenschr       Date:  1987-01-15

2.  The neurosurgeon and the blood-brain barrier. A survey.

Authors:  K G Go
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

3.  Acute effects of short-chain alkylglycerols on blood-brain barrier properties of cultured brain endothelial cells.

Authors:  P Hülper; S Veszelka; F R Walter; H Wolburg; P Fallier-Becker; J Piontek; I E Blasig; M Lakomek; W Kugler; M A Deli
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

4.  Effect of ether lipids on mouse granulocyte-macrophage progenitor cells.

Authors:  K Vehmeyer; D J Kim; G A Nagel; H Eibl; C Unger
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone.

Authors:  D Baker; J K O'Neill; A N Davison; J L Turk
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

6.  Brain uptake and CNS levels of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)urea (HECNU).

Authors:  C Unger; H Eibl; J Engel; G A Nagel; G Eisenbrand
Journal:  Invest New Drugs       Date:  1987-12       Impact factor: 3.850

Review 7.  Hexadecylphosphocholine: preclinical and the first clinical results of a new antitumor drug.

Authors:  C Unger; H Eibl
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

Review 8.  Trends in drug delivery through tissue barriers containing tight junctions.

Authors:  Christian Tscheik; Ingolf E Blasig; Lars Winkler
Journal:  Tissue Barriers       Date:  2013-04-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.